Ulcerative Necrobiosis Lipoidica: Is There a Place for Anti-TNFα Treatment? by Guedes, Rita et al.
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2012, Article ID 854738, 2 pages
doi:10.1155/2012/854738
Case Report
Ulcerative NecrobiosisLipoidica:Is There a Place
for Anti-TNFα Treatment?
Rita Guedes,Inˆ esLeite,Armando Baptista, andNatividadeRocha
Dermatology Department, Centro Hospitalar de Vila Nova de Gaia Espinho, Rua Conceic ¸˜ ao Fernandes,
4434-502 Vila Nova de Giaa, Portugal
Correspondence should be addressed to Rita Guedes, ritapereiraguedes@gmail.com
Received 13 December 2011; Accepted 28 March 2012
Academic Editor: Jeﬀrey M. Weinberg
Copyright © 2012 Rita Guedes et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Necrobiosislipoidicaisararegranulomatousandinﬂammatorydisease.Itsmanagementisparticularlydiﬃcultwhenulcerationis
present. The authors describe the clinical case of a 65-year-old female patient with necrobiosis lipoidica, who had been submitted
in the past to several topical and systemic treatments with little or no improvement. She started treatment with subcutaneous
etanercept and showed signiﬁcant improvement without adverse events until today. The aim of this article is to report a valid and
eﬃcient alternative treatment to recalcitrant cases.
1.Introduction
Necrobiosislipoidica(NL)isarare,idiopathic,chronicgran-
ulomatous inﬂammatory disorder. Ulceration occurs in up
to 35% of cases [1], leading to greater risk for secondary
infection and, in rare cases, to squamous cell carcinoma.
Until today there is no standardized eﬀective treatment.
We describe the clinical case of a 65-year-old female, type
2 diabetic patient, with a body mass index of 31,2 and a
clinical and histological diagnosis of necrobiosis lipoidica for
6 years (Figures 1(a) and 1(b)).
She had been previously submitted to several topical
and systemic treatments, namely, potent topical corti-
coids, topical 0.1% tacrolimus, and systemic cyclosporine
(3mg/kg/day). Topical corticoids and tacrolimus were inef-
fective. After 4 months of therapy with cyclosporine, she
achieved complete resolution of her lesions. However, due
to renal toxicity, the drug had to be stopped, with the
recurrence of the lesions. Four months later, we started
etanercept (50mg/week) subcutaneously and suspended all
the topic treatments done until then. At 8 weeks of therapy,
shehadallherulcerativelesionshealedandthebordersofthe
nonulcerated lesions were less inﬁltrated (Figure 2). To date,
she completed 6 months of 50mg weekly etanercept with no
adverse events.
2. Comment
Treatments for NL have had limited success, due either to
the unclear pathogenesis of the disease [2] or to signiﬁcant
side eﬀects associated with eﬀective treatments, namely,
worseningofdiabeteswithoralcorticoids,renaltoxicitywith
cyclosporine, medullar toxicity with mycophenolate mofetil,
and peripheral neuropathy with thalidomide. Moreover, the
relatively rarity of the disease makes randomized studies
diﬃcult to perform. Although many drugs have been used in
this pathology, none has demonstrated to be truly eﬀective.
Ulcerative lesions in diabetic patients, in particular, can be
a challenge, due to the pain associated with the topical
application of some agents or dressings and also due to
the scarce vascularity of the lesions, making reepithelization
diﬃcult.
TNF-α is an inﬂammatory cytokine with a role in cellu-
lar diﬀerentiation, mitogenesis, cytotoxicity, inﬂammation,
immunomodulation, and wound scarring. It seems to be
particularlyimportantinthedevelopmentofgranulomatous
inﬂammatory diseases, like NL. The inhibition of this
cytokine can be achieved with the use of a new drug class,
which at this moment is approved for rheumatoid arthritis,
psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic
arthritis, and psoriasis. Besides their oﬃcial indications,2 Case Reports in Medicine
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Figure 1: Ulcerative lesions on the patients’ shins (a) and feet (b).
Figure 2: Healed lesion after 12 weeks of therapy.
these drugs have been used with promising results in other
diseases [3].
Necrobiosis lipoidica nonresponsive to other therapeutic
agents,asagranulomatousdisease,hasbeentreatedwiththis
drug class since 2003 [4]. Inﬂiximab was the ﬁrst anti TNF-α
drugtobeprescribedinNL[4].However,duetointravenous
administration and frequent development of neutralizing
antibodies, one may prefer other options in the same drug
class. Nonulcerating NL treated with etanercept has already
been reported [2, 3, 5, 6] both with subcutaneous and with
intralesional injection; however, reports about the treatment
of ulcerative lesions are scarce. Su´ arez-Amor et al. reported
the successful treatment with etanercept of an ulcerative
NL patient nonresponsive to other ﬁrst-line treatments [1],
demonstrating that this drug can be an alternative drug in
resistant cases.
Our case reports the treatment of ulcerative NL with
etanercept, showing a superior eﬀect compared to cy-
closporine. Healing of the ulcerative lesions occurred during
a shorter period of therapy and with a favourable safety
proﬁle,showingthatitcanbeavalidoptionincasesinwhich
cyclosporine is contraindicated. The authors are aware of
possible side eﬀects of the drug, namely, the potential risk
of increased malignancies. Regarding necrobiosis lipoidica
etanercept could potentiate the transformation to squamous
cell carcinoma. However, due to the lack of response of
former treatments, this drug should be oﬀered to patients,
after explaining them these possible side eﬀects.
Therapeutic results presented in this clinical report
r a i s en e wq u e s t i o n sa b o u tT N F - α’s role in the disease and
suggest a therapeutic alternative for resistant cases to classic
treatments.Newreportsdescribingthemanagementofmore
patients will help to optimize therapeutic strategies.
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